|Bid||4.2100 x 800|
|Ask||4.5900 x 3200|
|Day's Range||4.1350 - 4.3813|
|52 Week Range||3.3500 - 11.6500|
|Beta (3Y Monthly)||3.23|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 6, 2019 - May 10, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.83|
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
Effective immediately, Andrew G. Long, chief financial officer, will take over as CEO, succeeding Saeed Motahari after the the two sides mutually agreed that Motahari should step down as president and CEO. "We believe that now is the right time to transition leadership and that Andy is an excellent choice to serve as the company's CEO," said board Chairman Steven Meyer. "On behalf of the Board, I thank Saeed for his commitment to Insys and meaningful contributions to the enterprise.
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that the Board of Directors has appointed Andrew G. Long as Chief Executive Officer, effective immediately. Mr. Long succeeds Saeed Motahari, who has mutually agreed with the INSYS Board of Directors to resign as President and CEO of the Company. In connection with INSYS’ leadership changes, Andrece Housley, INSYS’ Corporate Controller, has been appointed Chief Financial Officer, succeeding Mr. Long.
BOSTON (AP) — In a scheme to get doctors to write prescriptions in exchange for cash, a wealthy drug company founder put patients at risk to guarantee his business' success, a federal prosecutor told jurors Thursday in his closing arguments in the closely-watched trial.
The founder of Insys Therapeutics Inc put profits over patient safety by bribing doctors to prescribe an addictive fentanyl spray, fuelling the U.S. opioid epidemic, a federal prosecutor said on Thursday at the end of a landmark trial. John Kapoor, the drugmaker's former chairman, and four colleagues are the first executives of a painkiller manufacturer to face trial for conduct that authorities say was tied to a drug abuse epidemic that kills tens of thousands of Americans each year. Kapoor was arrested in 2017 on the same day U.S. President Donald Trump declared the opioid crisis a public health emergency.
Investors need to pay close attention to INSYS Therapeutics (INSY) stock based on the movements in the options market lately.
Insys Therapeutics (INSY) closed the most recent trading day at $4.62, moving +1.99% from the previous trading session.
INSYS Therapeutics, Inc. (INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the Company will present a poster of its pharmacokinetic (PK) study of its novel naloxone nasal spray versus intravenous and intramuscular injection at the College on Problems of Drug Dependence (CPDD)’s 81st Annual Scientific Meeting in San Antonio, Texas on Monday, June 17, 2019 at 8:00am Central Time. A copy of the poster will be made available on the Company’s website following the presentation. INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life.
Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.
Shares of opioid maker Insys Therapeutics Inc. dropped 27% on Wednesday after the company disclosed in a securities filing that an auditor had raised doubt about its ability to continue as a going concern. The company's founder, John Kapoor, and several former executives have been accused of bribing doctors to prescribe its drug Subsys, a sublingual fentanyl spray approved by the FDA for cancer pain. Fentanyl is an opioid that is up to 50 times more powerful than heroin. In August, the company agreed to pay $150 million over the next five years and a potential $75 million in additional payments to settle charges brought against it by the U.S. Department of Justice. The company's fourth-quarter operating expenses increased to $62.7 million from $47.5 million the year before, with much of the difference due to legal expenses. Although the company does not have any outstanding debt and currently has $104.1 million in cash, it said expects continued negative cash flows. As of December 31, Insys had an accumulated deficit of $336.1 million. Insys has two marketed products: Subsys, the fentanyl spray, and Syndros, an oral form of dronabinol for treating nausea and vomiting associated with chemotherapy. The company is also working on a naloxone nasal spray, an epinpehrine nasal spray and a cannabidiol oral solution for several indications including epilepsy in children. Shares of Insys have fallen 17% in the past three months, while the S&P 500 has gained 6.1%.
The Arizona-based company said the auditor's opinion on the audited financial statements for the year ended Dec. 31, 2018 flags uncertainty in its ability to generate enough cash to meet its legal obligations and sustain operations. Insys said that while it is looking for ways to raise capital, it can provide "no assurances" on the success of its efforts or that it would resolve its liquidity issues and wipe out operating losses. "If we are unable to obtain sufficient funding, we would need to significantly reduce our operating plans and curtail some or all of our product development, commercialization and strategic plans," the company said in a regulatory filing.
Insys Therapeutics Inc said on Wednesday its auditor raised doubts on the drugmaker's ability to continue as a going concern, sending its shares down 13 percent. The Arizona-based company said the auditor's opinion on the audited financial statements for the year ended Dec. 31, 2018 flags uncertainty in its ability to generate enough cash to meet its legal obligations and sustain operations. Insys said that while it is looking for ways to raise capital, it can provide "no assurances" on the success of its efforts or that it would resolve its liquidity issues and wipe out operating losses.
Insys Therapeutics Inc (NASDAQ:INSY) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
Janney analyst Yun Zhong reiterated a Buy rating on Insys with an $11 fair value estimate. The negative after-market reaction to Insys' financial results is attributable to investor concerns over declining opioid product net revenues, significant legal fees and a lack of clarity on the scale of liability associated with the former management, Zhong said in a Friday note. Amid the ongoing strategic review, the focus has shifted to Insys' pipeline, Stanicky said in a Thursday note.
Insys Therapeutics Inc said it tapped Lazard to advise the drugmaker on its plans to explore strategic options and is in talks to divest its fentanyl sublingual spray Subsys, sending the company's shares down 15 percent in after-hours trading. The company said in November it would review strategic alternatives for its portfolio of opioid-related assets, including Subsys. "We are in active negotiations with multiple parties regarding the potential divestiture of Subsys," Chief Executive Saeed Motahari said on Thursday, adding the company expects the transaction to require shareholder approval.